Printed from https://ideas.repec.org/s/spr/aphecp2.html
Content
September 2021, Volume 19, Issue 5
- 645-651 A Review of Web-Based Tools for Value-of-Information Analysis
by Haitham Tuffaha & Claire Rothery & Natalia Kunst & Chris Jackson & Mark Strong & Stephen Birch - 653-664 ‘What You See is All There is’: The Importance of Heuristics in Cost-Benefit Analysis (CBA) and Social Return on Investment (SROI) in the Evaluation of Public Health Interventions
by Rhiannon Tudor Edwards & Catherine Louise Lawrence - 665-672 The PLASMA System for Transurethral Resection of the Prostate: A NICE Medical Technologies Guidance Update
by Laura Knight & Susan Peirce & Rhys Morris - 673-697 A Systematic Review of the Costs Relating to Non-pharmaceutical Interventions Against Infectious Disease Outbreaks
by Janetta E. Skarp & Laura E. Downey & Julius W. E. Ohrnberger & Lucia Cilloni & Alexandra B. Hogan & Abagael L. Sykes & Susannah S. Wang & Hiral Anil Shah & Mimi Xiao & Katharina Hauck - 699-708 Using Constrained Optimization for the Allocation of COVID-19 Vaccines in the Philippines
by Christian Alvin H. Buhat & Destiny S. M. Lutero & Yancee H. Olave & Kemuel M. Quindala & Mary Grace P. Recreo & Dylan Antonio S. J. Talabis & Monica C. Torres & Jerrold M. Tubay & Jomar F. Rabajante - 709-719 How Much Money Should be Paid for a Patient to Isolate During the COVID-19 Outbreak? A Discrete Choice Experiment in Iran
by Enayatollah Homaie Rad & Mohammad Hajizadeh & Vahid Yazdi-Feyzabadi & Sajad Delavari & Zahra Mohtasham-Amiri - 721-733 The Impact of Financing Health Services on Income Inequality in an Unequal Society: The Case of South Africa
by John E. Ataguba - 735-745 Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
by Han Geul Byun & Minyoung Jang & Hyun Kyeong Yoo & James Potter & Taek Sang Kwon - 747-756 Incorporating Process Utility into Cost-Effectiveness Analysis via a Bolt-On Domain to the SF-6D: An Exploratory Study
by Victoria K. Brennan & Georgina Jones & Stephen Radley & Simon Dixon - 757-767 Consumers' Preferences and Willingness to Pay for Personalised Nutrition
by Daniel Pérez-Troncoso & David M. Epstein & José A. Castañeda-García - 769-782 Disease-Specific Out-of-Pocket Payments, Catastrophic Health Expenditure and Impoverishment Effects in India: An Analysis of National Health Survey Data
by Jeetendra Yadav & Geetha R. Menon & Denny John - 783-784 Comment on: “Disease-Specific Out-of-Pocket Payments, Catastrophic Health Expenditure and Impoverishment Effects in India: An Analysis of National Health Survey Data”
by Nafis Faizi & Yasir Alvi
July 2021, Volume 19, Issue 4
- 453-461 Cost of Medicare for All: Review of the Estimates
by John A. Nyman - 463-472 Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines
by Chris Painter & Wanrudee Isaranuwatchai & Juthamas Prawjaeng & Hwee Lin Wee & Brandon Wen Bing Chua & Vinh Anh Huynh & Jing Lou & Fang Ting Goh & Nantasit Luangasanatip & Wirichada Pan-Ngum & Wang Yi & Hannah Clapham & Yot Teerawattananon - 473-486 Cost-effectiveness of Interventions for Chronic Fatigue Syndrome or Myalgic Encephalomyelitis: A Systematic Review of Economic Evaluations
by M. Cochrane & E. Mitchell & W. Hollingworth & E. Crawley & D. Trépel - 487-499 Economic Analyses of Pathogen-Reduction Technologies in Blood Transfusion: A Systematic Literature Review
by Patrick R. LaFontaine & Jing Yuan & Katherine M. Prioli & Priti Shah & Jay H. Herman & Laura T. Pizzi - 501-520 Costs of Illness of Spinal Muscular Atrophy: A Systematic Review
by Erik Landfeldt & Astrid Pechmann & Hugh J. McMillan & Hanns Lochmüller & Thomas Sejersen - 521-535 Preferences for Medical Consultations from Online Providers: Evidence from a Discrete Choice Experiment in the United Kingdom
by James Buchanan & Laurence S. J. Roope & Liz Morrell & Koen B. Pouwels & Julie V. Robotham & Lucy Abel & Derrick W. Crook & Tim Peto & Christopher C. Butler & A. Sarah Walker & Sarah Wordsworth - 537-544 Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time-Series Analysis
by George Dranitsaris & Carlo DeAngelis & Blake Pearson & Laura McDermott & Bernd Pohlmann-Eden - 545-555 Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea
by Siin Kim & Sola Han & Hyungtae Kim & Hae Sun Suh - 557-577 The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil
by Wânia Cristina Silva & Brian Godman & Francisco Acúrcio & Mariângela Leal Cherchiglia & Antony Martin & Konrad Maruszczyk & Jans Bastos Izidoro & Marcos André Portella & Agner Pereira Lana & Orozimbo Henriques Campos Neto & Eli Iola Gurgel Andrade - 579-591 The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data
by Cathrine Elgaard Jensen & Sabrina Storgaard Sørensen & Claire Gudex & Morten Berg Jensen & Kjeld Møller Pedersen & Lars Holger Ehlers - 593-604 Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn’s Disease
by Tomas Mlcoch & Barbora Decker & Tomas Dolezal - 605-618 Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives
by Jingyan Yang & Rongzhe Liu & Varun Ektare & Jennifer Stephens & Ahmed Shelbaya - 619-621 Comment on: “Willingness to Pay for a COVID-19 Vaccine”
by Philipp Sprengholz & Cornelia Betsch - 623-624 Authors’ Reply to Sprengholz and Betsch: “Willingness to Pay for a COVID-19 Vaccine”
by Leidy Y. García & Arcadio A. Cerda
May 2021, Volume 19, Issue 3
- 281-304 Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries
by Yitong Wang & Tingting Qiu & Junwen Zhou & Clément Francois & Mondher Toumi - 305-312 Copula Models for Addressing Sample Selection in the Evaluation of Public Health Programmes: An Application to the Leeds Let’s Get Active Study
by Paolo Candio & Andrew J. Hill & Stavros Poupakis & Anni-Maria Pulkki-Brännström & Chris Bojke & Manuel Gomes - 313-324 The Cost-Effectiveness of Pulmonary Rehabilitation for COPD in Different Settings: A Systematic Review
by Shengnan Liu & Qiheng Zhao & Wenshuo Li & Xuetong Zhao & Kun Li - 325-341 The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review
by Nicolas Iragorri & Claire Oliveira & Natalie Fitzgerald & Beverley Essue - 343-351 Willingness to Pay for a COVID-19 Vaccine
by Arcadio A. Cerda & Leidy Y. García - 353-370 Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India's National Publicly Financed Health Insurance Scheme
by Shankar Prinja & Maninder Pal Singh & Kavitha Rajsekar & Oshima Sachin & Praveen Gedam & Anu Nagar & Balram Bhargava - 371-387 Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C
by Pingyu Chen & Min Jin & Yang Cao & Hongchao Li - 389-401 What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches
by Anthony J. Hatswell & Ash Bullement & Michael Schlichting & Murtuza Bharmal - 403-414 Potential Unintended Consequences of National Infectious Disease Screening Strategies in Deceased Donor Kidney Transplantation: A Cost-Effectiveness Analysis
by Trevor A. Ellison & Samantha Clark & Jonathan C. Hong & Kevin D. Frick & Dorry L. Segev - 415-428 Prescription Drug Monitoring Programs and Opioid Prescriptions for Disability Conditions
by Orgul Ozturk & Yuan Hong & Suzanne McDermott & Margaret Turk - 429-437 Management of Chest Indrawing Pneumonia in Children Under Five Years at the Outpatient Health Facilities in Nigeria: An Economic Evaluation
by Charles E. Okafor - 439-450 Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies
by Sun-Hong Kwon & Hea-Sun Park & Young-Jin Na & Chul Park & Ju-Young Shin & Hye-Lin Kim - 451-451 Correction to: Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India’s National Publicly Financed Health Insurance Scheme
by Shankar Prinja & Maninder Pal Singh & Kavitha Rajsekar & Oshima Sachin & Praveen Gedam & Anu Nagar & Balram Bhargava
March 2021, Volume 19, Issue 2
- 141-144 The Vatican City State Internal Healthcare System Response to COVID-19 Pandemic: Prevention and Control Strategies
by Andrea Arcangeli & Massimo Ralli & Fabio De-Giorgio & Paolo Maurizio Soave & Lucia Ercoli - 145-153 Curos™ Disinfection Caps for the Prevention of Infection When Using Needleless Connectors: A NICE Medical Technologies Guidance
by Susan O’Connell & Megan Dale & Helen Morgan & Kimberley Carter & Grace Carolan-Rees - 155-162 Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review
by William V. Padula & Hui-Han Chen & Charles E. Phelps - 163-180 The Cost-Effectiveness of Kidney Replacement Therapy Modalities: A Systematic Review of Full Economic Evaluations
by Fei Yang & Meixia Liao & Pusheng Wang & Zheng Yang & Yongguang Liu - 181-190 How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany
by Afschin Gandjour - 191-202 French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30
by Virginie Nerich & Eva Maria Gamper & Richard Norman & Madeleine King & Bernhard Holzner & Rosalie Viney & Georg Kemmler - 203-215 Cost Effectiveness of Case Detection Strategies for the Early Detection of COPD
by Kate M. Johnson & Mohsen Sadatsafavi & Amin Adibi & Larry Lynd & Mark Harrison & Hamid Tavakoli & Don D. Sin & Stirling Bryan - 217-229 Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
by Mujaheed Shaikh & Pietro Giudice & Dimitrios Kourouklis - 231-241 Budget Impact of Microbial Cell-Free DNA Testing Using the Karius® Test as an Alternative to Invasive Procedures in Immunocompromised Patients with Suspected Invasive Fungal Infections
by Ann T. MacIntyre & Alex Hirst & Radha Duttagupta & Desiree Hollemon & David K. Hong & Timothy A. Blauwkamp - 243-252 Impact of Guidelines on the Diffusion of Medical Technology: A Case Study of Cardiac Resynchronization Therapy in the UK
by Rucha Vadia & Tom Stargardt - 253-266 Identifying Community Pharmacist Preferences For Prescribing Services in Primary Care in New Zealand: A Discrete Choice Experiment
by Rakhee Raghunandan & Kirsten Howard & Carlo A. Marra & June Tordoff & Alesha Smith - 267-277 Cost Effectiveness of Introducing Etonorgestrel Contraceptive Implant into India’s Current Family Welfare Programme
by Beena Joshi & Kusum V. Moray & Oshima Sachin & Himanshu Chaurasia & Shahina Begum - 279-279 Correction to: Cost Effectiveness of Introducing Etonorgestrel Contraceptive Implant into India’s Current Family Welfare Programme
by Beena Joshi & Kusum V. Moray & Oshima Sachin & Himanshu Chaurasia & Shahina Begum
January 2021, Volume 19, Issue 1
- 5-8 Economic Theory and Medical Assistance in Dying
by Donald A. Redelmeier & Allan S. Detsky - 9-15 Using a Formal Strategy of Priority Setting to Mitigate Austerity Effects Through Gains in Value: The Role of Program Budgeting and Marginal Analysis (PBMA) in the Brazilian Public Healthcare System
by Brayan V. Seixas & Craig Mitton - 17-27 Systematic Review and Critique of Methods for Economic Evaluation of Digital Mental Health Interventions
by Dina Jankovic & Laura Bojke & David Marshall & Pedro Saramago Goncalves & Rachel Churchill & Hollie Melton & Sally Brabyn & Lina Gega - 29-44 Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results
by Ru Han & Clément François & Mondher Toumi - 45-56 Elections have Consequences: Partisan Politics may be Literally Killing Us
by Alexander Maas & Liang Lu - 57-68 Cardiac Resynchronisation Therapy in Patients with Moderate to Severe Heart Failure in Germany: A Cost-Utility Analysis of the Additional Defibrillator
by Moritz Hadwiger & Fabian-Simon Frielitz & Nora Eisemann & Christian Elsner & Nikolaos Dagres & Gerhard Hindricks & Alexander Katalinic - 69-79 Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
by Shanshan Hu & Xun Deng & Yanjiao Ma & Zhilei Li & Yuhang Wang & Yong Wang - 81-96 Availability and Variability of Consumer Prices for Lumbar Discectomy Across US Hospitals in 2018
by Alexander J. Butler & Caroline J. Granger & Sebastian Rivera & Chester J. Donnally & Alexander Ghasem & Deborah Li & Michael Y. Wang - 97-109 Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer
by Julia Simoes Correa-Galendi & Maria Pilar Estevez Diz & Stephanie Stock & Dirk Müller - 111-121 Using Eye-Tracking Technology with Older People in Memory Clinics to Investigate the Impact of Mild Cognitive Impairment on Choices for EQ-5D-5L Health States Preferences
by Kaiying Wang & Chris Barr & Richard Norman & Stacey George & Craig Whitehead & Julie Ratcliffe - 123-132 Economic Evaluation of Senshio® (Ospemifene) for the Treatment of Vulvovaginal Atrophy in Scotland
by Amy Dymond & Hayden Holmes & Jessica McMaster & Joyce Craig & Heather Davies & Stuart Mealing & Rodolphe Perard - 133-140 Effect of an Online Reimbursement Application System on Prescribing of Lidocaine 5% Medicated Plaster in the Republic of Ireland
by Amelia Smith & Stephen Doran & Maria Daly & Cormac Kennedy & Michael Barry
December 2020, Volume 18, Issue 6
- 743-746 Health Financing in Sub-Saharan Africa: From Analytical Frameworks to Empirical Evaluation
by Augustine Asante & Wilson S. K. Wasike & John E. Ataguba - 747-757 An Alternative Approach to Decomposing the Redistributive Effect of Health Financing Between and Within Groups Using the Gini Index: The Case of Out-of-Pocket Payments in Nigeria
by John E. Ataguba & Hyacinth E. Ichoku & Chijioke O. Nwosu & James Akazili - 759-766 Evaluating Equity in Health Financing Using Benefit Incidence Analysis: A Framework for Accounting for Quality of Care
by Augustine Asante & Nicola Man & Virginia Wiseman - 767-780 Analyzing the Financial Sustainability of User Fee Removal Policies: A Rapid First Assessment Methodology with a Practical Application for Burkina Faso
by Jacky Mathonnat & Martine Audibert & Salam Belem - 781-788 Estimating Catastrophic Health Expenditures from Household Surveys: Evidence from Living Standard Measurement Surveys (LSMS)-Integrated Surveys on Agriculture (ISA) from Sub-Saharan Africa
by Sarah Ssewanyana & Ibrahim Kasirye - 789-799 An Assessment of Domestic Financing for Reproductive, Maternal, Neonatal and Child Health in Sub-Saharan Africa: Potential Gains and Fiscal Space
by Chris Atim & Eric Arthur & Daniel Malik Achala & Jacob Novignon - 801-810 Performance-Based Financing, Basic Packages of Health Services and User-Fee Exemption Mechanisms: An Analysis of Health-Financing Policy Integration in Three Fragile and Conflict-Affected Settings
by Eelco Jacobs & Maria Paola Bertone & Jurrien Toonen & Ngozi Akwataghibe & Sophie Witter - 811-823 Payment Arrangements for Private Healthcare Purchasing Under Publicly Funded Systems in Low- and Middle-Income Countries: Issues and Implications
by Ayako Honda & Amarech Obse - 825-840 Health Insurance in Sub-Saharan Africa: A Scoping Review of the Methods Used to Evaluate its Impact
by Stéphanie Degroote & Valery Ridde & Manuela Allegri
October 2020, Volume 18, Issue 5
- 597-599 The Inclusion of Comparative Environmental Impact in Health Technology Assessment: Practical Barriers and Unintended Consequences
by Brita A. K. Pekarsky - 601-604 Modeling Medicaid and Medicare Savings from Reduced Poverty and Disability to Promote Investment in Mental Health and Substance Use Interventions in the USA
by Nathaniel Z. Counts & Paul Gionfriddo & Richard H. Chapman - 605-623 Health Promoting Schools: An Update
by Albert Lee & Amelia Lo & Queenie Li & Vera Keung & Amy Kwong - 625-639 A Systematic Review of the Association Between Hospital Cost/price and the Quality of Care
by Sara Jamalabadi & Vera Winter & Jonas Schreyögg - 641-654 Factors Influencing the Cost-Effectiveness Outcomes of HPV Vaccination and Screening Interventions in Low-to-Middle-Income Countries (LMICs): A Systematic Review
by Bernard O. Okeah & Colin H. Ridyard - 655-667 Effects of Monetary Incentives in Physician Groups: A Systematic Review of Reviews
by Ann-Kathrin Heider & Harald Mang - 669-677 The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis
by Jakub P. Hlávka & Soeren Mattke & Asa Wilks - 679-687 Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases
by Anh Dam Tran & Gerald Fogarty & Anna K. Nowak & Vakaramoko Diaby & Angela Hong & Caroline Watts & Rachael L. Morton - 689-698 Preferences for Weight Loss Treatment Amongst Treatment-Seeking Patients with Severe Obesity: A Discrete Choice Experiment
by Michelle Queally & Edel Doherty & Francis Finucane & Ciaran O’Neill - 699-711 Estimating the Unit Costs of Healthcare Service Delivery in India: Addressing Information Gaps for Price Setting and Health Technology Assessment
by Pankaj Bahuguna & Lorna Guinness & Sameer Sharma & Akashdeep Singh Chauhan & Laura Downey & Shankar Prinja - 713-726 Implementing Lifestyle Change Interventions to Prevent Type 2 Diabetes in US Medicaid Programs: Cost Effectiveness, and Cost, Health, and Health Equity Impact
by Michael Laxy & Ping Zhang & Boon Peng Ng & Hui Shao & Mohammed K. Ali & Ann Albright & Edward W. Gregg - 727-737 Cost-Effectiveness Analysis of Supervised Exercise Training in Men with Prostate Cancer Previously Treated with Radiation Therapy and Androgen-Deprivation Therapy
by Kim Edmunds & Penny Reeves & Paul Scuffham & Daniel A. Galvão & Robert U. Newton & Mark Jones & Nigel Spry & Dennis R. Taaffe & David Joseph & Suzanne K. Chambers & Haitham Tuffaha - 739-741 Comment on: “The Italian NHS: What Lessons to Draw from COVID-19?”
by Davide Golinelli & Andrea Bucci & Kadjo Yves Cedric Adja & Fabrizio Toscano
August 2020, Volume 18, Issue 4
- 461-462 The Potential Role of Constrained Optimization Methods in Healthcare Decision Making
by William H. Crown - 463-466 The Italian NHS: What Lessons to Draw from COVID-19?
by Livio Garattini & Michele Zanetti & Nicholas Freemantle - 467-475 Should Health Economic Evaluations Undertaken from a Societal Perspective Include Net Government Spending Multiplier Effects?
by Jonathan Karnon & Brita Pekarsky - 477-489 Do Research Groups Align on an Intervention’s Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders
by Matthew Sussman & Jeffrey C. Yu & Joseph Menzin - 491-508 Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review
by Elsa Bouée-Benhamiche & Philippe Jean Bousquet & Salah Ghabri - 509-517 The Efficacy of Lockdown Against COVID-19: A Cross-Country Panel Analysis
by Vincenzo Alfano & Salvatore Ercolano - 519-531 Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project
by Baudouin Standaert & Ilse Van Vlaenderen & Laure-Anne Van Bellinghen & Sandra Talbird & Katherine Hicks & Justin Carrico & Philip O. Buck - 533-545 Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA
by Mustafa Oguz & Tereza Lanitis & Xiaoyan Li & Gail Wygant & Daniel E. Singer & Keith Friend & Patrick Hlavacek & Andreas Nikolaou & Soeren Mattke - 547-556 Health State Values of Deaf British Sign Language (BSL) Users in the UK: An Application of the BSL Version of the EQ-5D-5L
by Gemma E. Shields & Katherine D. Rogers & Alys Young & Sofia Dedotsi & Linda M. Davies - 557-566 Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea
by Hye-Jae Lee & Euna Han & Hyero Kim - 567-578 Cost–Utility of Internet-Based Cognitive Behavioral Therapy in Unipolar Depression: A Markov Model Simulation
by Mathias Baumann & Tom Stargardt & Simon Frey - 579-587 Estimating the Productivity Burden of Pediatric Pneumococcal Disease in Thailand
by Thanpisit Ounsirithupsakul & Piyameth Dilokthornsakul & Khachen Kongpakwattana & Zanfina Ademi & Danny Liew & Nathorn Chaiyakunapruk - 589-596 What Matters to Potential Patients in Chemotherapy Service Delivery? A Discrete Choice Experiment
by Richard Norman & Matthew Anstey & Arman Hasani & Ian Li & Suzanne Robinson
June 2020, Volume 18, Issue 3
- 325-328 COVID-19 Pandemic, a War to be Won: Understanding its Economic Implications for Africa
by John E. Ataguba - 329-331 A Simple Decision Analysis of a Mandatory Lockdown Response to the COVID-19 Pandemic
by Jonathan Karnon - 333-334 Why Only Test Symptomatic Patients? Consider Random Screening for COVID-19
by William V. Padula - 335-337 The Case for a Temporary COVID-19 Income Tax Levy Now, During the Crisis
by Jonathan Karnon - 339-343 Impact of a Global Pandemic on Health Technology Assessment
by Paula K. Lorgelly & Amanda Adler - 345-350 Using Insights from Behavioral Economics to Mitigate the Spread of COVID-19
by Moslem Soofi & Farid Najafi & Behzad Karami-Matin - 351-356 The Relevant Perspective of Economic Evaluations Informing Local Decision Makers: An Exploration in Weight Loss Services
by Sebastian Hinde & Louise Horsfield & Laura Bojke & Gerry Richardson - 357-362 Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition
by Rosella Levaggi & Paolo Pertile - 363-373 iFuse Implant System for Treating Chronic Sacroiliac Joint Pain: A NICE Medical Technology Guidance
by Megan Dale & James Evans & Kimberley Carter & Susan O’Connell & Helen Morgan & Grace Carolan-Rees - 375-392 Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists
by Chiranjeev Sanyal & Don Husereau - 393-411 Cost-Effectiveness of Therapeutic Use of Safety-Engineered Syringes in Healthcare Facilities in India
by Pankaj Bahuguna & Shankar Prinja & Chandrakant Lahariya & Radha Krishan Dhiman & Madhumita Prem Kumar & Vineeta Sharma & Arun Kumar Aggarwal & Rajesh Bhaskar & Hilde Graeve & Henk Bekedam - 413-432 Promoting HIV Testing by Men: A Discrete Choice Experiment to Elicit Preferences and Predict Uptake of Community-based Testing in Uganda
by Elisabeth M. Schaffer & Juan Marcos Gonzalez & Stephanie B. Wheeler & Dalsone Kwarisiima & Gabriel Chamie & Harsha Thirumurthy - 433-442 Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT® Re-usable Inhaler
by Gustaf Ortsäter & Fredrik Borgström & Mike Baldwin & Carolin Miltenburger - 443-451 The Impact of Physicians’ Working Hours on Inappropriate Use of Outpatient Medicine in a Tertiary Hospital in China
by Xiaodong Guan & Bingyu Ni & Jingyuan Zhang & Chunxia Man & Zheng Cai & Wenshuang Meng & Luwen Shi & Dennis Ross-Degnan - 453-454 Comment on: ‘Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition’
by Livio Garattini & Nick Freemantle - 455-456 Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”
by Rosella Levaggi & Paolo Pertile - 457-458 Comment on: “A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance”
by J. P. Hays - 459-460 Authors’ Reply to Hays: “A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance”
by David J. Mott & Grace Hampson & Martin J. Llewelyn & Jorge Mestre-Ferrandiz & Michael M. Hopkins
April 2020, Volume 18, Issue 2
- 143-145 Economics of Mental Health: Providing a Platform for Efficient Mental Health Policy
by Christopher M. Doran & Irina Kinchin - 147-153 Mental health: A Particular Challenge Confronting Policy Makers and Economists
by Peter Zweifel - 155-175 Universal Mental Health Interventions for Children and Adolescents: A Systematic Review of Health Economic Evaluations
by Masja Schmidt & Amber Werbrouck & Nick Verhaeghe & Koen Putman & Steven Simoens & Lieven Annemans - 177-188 Healthcare Costs for People with Serious Mental Illness in England: An Analysis of Costs Across Primary Care, Hospital Care, and Specialist Mental Healthcare
by Jemimah Ride & Panagiotis Kasteridis & Nils Gutacker & Maria Jose Aragon Aragon & Rowena Jacobs - 189-201 Evaluating the Cost Effectiveness of a Suicide Prevention Campaign Implemented in Ontario, Canada
by Michael Lebenbaum & Joyce Cheng & Claire Oliveira & Paul Kurdyak & Juveria Zaheer & Rebecca Hancock-Howard & Peter C. Coyte - 203-221 The Evolution of Mental Health in the Context of Transitory Economic Changes
by Alexandrina Stoyanova & Jaime Pinilla - 223-235 Socioeconomic Disparities in Unmet Need for Student Mental Health Services in Higher Education
by John Cullinan & Sharon Walsh & Darragh Flannery - 237-247 Cost-Effectiveness of Dementia Care Mapping in Care-Home Settings: Evaluation of a Randomised Controlled Trial
by David M. Meads & Adam Martin & Alys Griffiths & Rachael Kelley & Byron Creese & Louise Robinson & Joanne McDermid & Rebecca Walwyn & Clive Ballard & Claire A. Surr - 249-259 The Impact of Ghana’s National Health Insurance on Psychological Distress
by Gowokani Chijere Chirwa & Marc Suhrcke & Rodrigo Moreno-Serra - 261-270 Implicitly Estimating the Cost of Mental Illness in Australia: A Standard-of-Living Approach
by Son Nghiem & Rasheda Khanam & Xuan-Binh Vu & Bach Xuan Tran - 271-285 Cost-Effectiveness of a School-Based Social and Emotional Learning Intervention: Evidence from a Cluster-Randomised Controlled Trial of the Promoting Alternative Thinking Strategies Curriculum
by Alex J. Turner & Matt Sutton & Mark Harrison & Alexandra Hennessey & Neil Humphrey - 287-298 Costs of Mental Health Services in Czechia: Facilitating an Evidence-Based Reform of Psychiatric Care
by Hana M. Broulíková & Petr Winkler & Marek Páv & Lucie Kondrátová - 299-309 Assessing Horizontal Equity in the Utilization of Mental Healthcare Services in Turkey: A Gender Perspective
by Dilek Başar & Selcen Öztürk - 311-324 Program Evaluation and Decision Analytic Modelling of Universal Suicide Prevention Training (safeTALK) in Secondary Schools
by Irina Kinchin & Alex M. T. Russell & Dennis Petrie & Adrianne Mifsud & Laurence Manning & Christopher M. Doran
February 2020, Volume 18, Issue 1
- 1-4 Improving Decision-Making Processes in Health: Is It Time for (Disease-Specific) Reference Models?
by Hossein Haji Ali Afzali & Laura Bojke & Jonathan Karnon - 5-16 Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab
by Caridad Pontes & Corinne Zara & Josep Torrent-Farnell & Merce Obach & Cristina Nadal & Patricia Vella-Bonanno & Michael Ermisch & Steven Simoens & Renata Curi Hauegen & Jolanta Gulbinovic & Angela Timoney & Antony P. Martin & Tanja Mueller & Anna Nachtnebel & Stephen Campbell & Gisbert Selke & Tomasz Bochenek & Celia C. Rothe & Ileana Mardare & Marion Bennie & Jurij Fürst & Rickard E. Malmstrom & Brian Godman - 17-29 Determining the Baseline Strategy in a Cost-Effectiveness Analysis with Treatment Sequences
by Marta Giulia Viola & Alexander Diamantopoulos - 31-46 Using the Threshold Technique to Elicit Patient Preferences: An Introduction to the Method and an Overview of Existing Empirical Applications
by Brett Hauber & Joshua Coulter - 47-56 Price Models for Multi-indication Drugs: A Systematic Review
by Carlos Campillo-Artero & Jaume Puig-Junoy & José Luis Segú-Tolsa & Marta Trapero-Bertran - 57-68 Cost-utility Analysis of Opportunistic and Systematic Diabetic Retinopathy Screening Strategies from the Perspective of the Brazilian Public Healthcare System
by Ângela J. Ben & Jeruza L. Neyeloff & Camila F. Souza & Ana Paula O. Rosses & Aline L. Araujo & Adriana Szortika & Franciele Locatelli & Gabriela Carvalho & Cristina R. Neumann - 69-79 A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance
by David J. Mott & Grace Hampson & Martin J. Llewelyn & Jorge Mestre-Ferrandiz & Michael M. Hopkins - 81-96 Why Do Informal Sector Workers Not Pay the Premium Regularly? Evidence from the National Health Insurance System in Indonesia
by Teguh Dartanto & Alin Halimatussadiah & Jahen Fachrul Rezki & Renny Nurhasana & Chairina Hanum Siregar & Hamdan Bintara & Usman & Wahyu Pramono & Nia Kurnia Sholihah & Edith Zheng Wen Yuan & Rooswanti Soeharno - 97-107 Estimating Attribute-Specific Willingness-to-Pay Values from a Health Care Contingent Valuation Study: A Best–Worst Choice Approach
by Ivan Sever & Miroslav Verbič & Eva Klaric Sever - 109-125 Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany
by Afschin Gandjour & Dennis A. Ostwald - 127-137 Forecasting Ontario Oncology Drug Expenditures: A Hybrid Approach to Improving Accuracy
by Paula M. Murray & Yusuf A. Shalaby & Luciano Ieraci & Emmett Borg & Daphne Sniekers & Ali Vahit Esensoy & Jessica Arias - 139-140 Comment on: “Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection Under Different Treatment Policies in Malaysia, 2018–2040”
by Muhammad Radzi Abu Hassan & Huan-Keat Chan - 141-141 Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
by Renée Else Michels & Maria Francesco & Koshu Mahajan & Gerald J. D. Hengstman & Krijn M. H. Schiffers & Sangeeta Budhia & Gerard Harty & Marieke Krol
December 2019, Volume 17, Issue 6
- 757-759 Expanding the Role of the Patient-Centered Outcomes Research Institute: Reauthorization and Facilitating Value Assessments
by William V. Padula & R. Brett McQueen - 761-770 A Framework to Prioritise Health Research Proposals for Funding: Integrating Value for Money
by Haitham W. Tuffaha & Joanne Aitken & Suzanne Chambers & Paul A. Scuffham - 771-780 A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
by Ash Bullement & Holly L. Cranmer & Gemma E. Shields - 781-801 A Review of the Development and Application of Generic Preference-Based Instruments with the Older Population
by Jenny Cleland & Claire Hutchinson & Jyoti Khadka & Rachel Milte & Julie Ratcliffe - 803-816 Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries
by Sabine Vogler & Guillaume Dedet & Hanne Bak Pedersen - 817-825 The Value Employees Place on Health Insurance Plans: A Discrete-Choice Experiment
by Stephen Poteet & Benjamin M. Craig - 827-839 Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting
by Gabriel Tremblay & Ben Rousseau & Miriam Marquis & Cyrielle Beaubois & Guy Sauvageau & Josée Hébert - 841-855 Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial
by Marcel Bilger & Tina T. Wong & Jia Yi Lee & Kaye L. Howard & Filipinas G. Bundoc & Ecosse L. Lamoureux & Eric A. Finkelstein - 857-873 Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
by Renée Else Michels & Maria Fransesco & Koshu Mahajan & Gerald J. D. Hengstman & Krijn M. H. Schiffers & Sangeeta Budhia & Gerard Harty & Marieke Krol - 875-882 In-Hospital Healthcare Utilization, Outcomes, and Costs in Pre-Hospital-Adjudicated Low-Risk Chest-Pain Patients
by Dominique N. Dongen & Jan Paul Ottervanger & Rudolf Tolsma & Marion Fokkert & Aize Sluis & Arnoud W. J. ‘t Hof & Erik Badings & Robbert J. Slingerland - 883-893 Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
by Rick A. Vreman & Joost W. Geenen & Anke M. Hövels & Wim G. Goettsch & Hubert G. M. Leufkens & Maiwenn J. Al - 895-902 What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population
by Kim Pauwels & Isabelle Huys & Minne Casteels & Yvonne Denier & Martina Vandebroek & Steven Simoens
October 2019, Volume 17, Issue 5
- 573-576 Health Technology Assessment as Part of a Broader Process for Priority Setting and Resource Allocation
by Craig Mitton & Brayan V. Seixas & Stuart Peacock & Michael Burgess & Stirling Bryan - 577-590 Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers
by Simon Walker & Susan Griffin & Miqdad Asaria & Aki Tsuchiya & Mark Sculpher - 591-613 A Systematic Review of Productivity in Economic Evaluations of Workplace Interventions: A Need for Reporting Criteria?
by Cheryl Jones & Suzanne M. M. Verstappen & Katherine Payne - 615-627 Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
by Richard F. Pollock & William J. Valentine & Steven P. Marso & Andreas Andersen & Jens Gundgaard & Nino Hallén & Deniz Tutkunkardas & Elizabeth A. Magnuson & John B. Buse - 629-640 The Economic Burden of Asthma in Greece: A Cross-Sectional Study
by Katerina Vellopoulou & Petros Bakakos & Stelios Loukides & Nikos Maniadakis & Georgia Kourlaba - 641-654 Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy
by Shui Ling Wong & Saliza Ibrahim & Norazlin Abdul Kadir & Salbiah Mohd Salleh - 655-667 Budget Impact Analysis of Molecular Lymph Node Staging Versus Conventional Histopathology Staging in Colorectal Carcinoma
by Sherley Diaz-Mercedes & Ivan Archilla & Jordi Camps & Antonio Lacy & Iñigo Gorostiaga & Dulce Momblan & Ainitze Ibarzabal & Joan Maurel & Nuria Chic & Josep Antoni Bombí & Francesc Balaguer & Antoni Castells & Iban Aldecoa & Josep Maria Borras & Miriam Cuatrecasas - 669-681 Cost-Effectiveness of a Psycho-Educational Intervention Targeting Fear of Cancer Recurrence in People Treated for Early-Stage Melanoma
by Mbathio Dieng & Nikita Khanna & Nadine A. Kasparian & Daniel S. J. Costa & Phyllis N. Butow & Scott W. Menzies & Graham J. Mann & Anne E Cust & Rachael L. Morton - 683-705 Developing Attributes and Attribute-Levels for a Discrete-Choice Experiment: An Example for Interventions of Impulsive Violent Offenders
by Stella Nalukwago Settumba & Marian Shanahan & Tony Butler & Peter Schofield & Lise Lafferty & Paul Simpson & Georgina M. Chambers - 707-722 General Trends in Prices and Prescription Patterns of Anticonvulsants in Germany between 2000 and 2017: Analysis of National and Cohort-Based Data
by Laurent M. Willems & Hajo M. Hamer & Susanne Knake & Felix Rosenow & Jens-Peter Reese & Adam Strzelczyk - 723-732 Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
by Ashleigh McGirr & Desiree Van Oorschot & Robyn Widenmaier & Michael Stokes & Michael L. Ganz & Hyosung Jung & Lijoy Varghese & Desmond Curran - 733-740 Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA
by Lotte Steuten & Vincent Garmo & Hemant Phatak & Sean D. Sullivan & Paul Nghiem & Scott D. Ramsey - 741-751 A Probe into the Wages and Salaries of Health Economics, Outcomes Research, and Market Access Professionals
by Manuel J. Carvajal & Patti Peeples & Ioana Popovici
August 2019, Volume 17, Issue 4
- 421-431 Why is There Discordance between the Reimbursement of High-Cost ‘Life-Extending’ Pharmaceuticals and Medical Devices? The Funding of Ventricular Assist Devices in Australia
by Sopany Saing & Naomi van der Linden & Christopher Hayward & Stephen Goodall - 433-441 Advanced Data Visualisation in Health Economics and Outcomes Research: Opportunities and Challenges
by Shelagh M. Szabo & Karissa M. Johnston & Andrew J. Lloyd - 443-452 A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine
by Patrick Fahr & James Buchanan & Sarah Wordsworth - 453-465 Mepilex Border Sacrum and Heel Dressings for the Prevention of Pressure Ulcers: A NICE Medical Technology Guidance
by C. Marshall & J. Shore & M. Arber & M. Cikalo & T. Oladapo & A. Peel & R. McCool & Michelle Jenks - 467-491 Systematic Review of Decision Analytic Modelling in Economic Evaluations of Low Back Pain and Sciatica
by James A. Hall & Kika Konstantinou & Martyn Lewis & Raymond Oppong & Reuben Ogollah & Sue Jowett - 493-511 Budget Impact Analysis of Cancer Screening: A Methodological Review
by Beate Jahn & Jovan Todorovic & Marvin Bundo & Gaby Sroczynski & Annette Conrads-Frank & Ursula Rochau & Gottfried Endel & Ingrid Wilbacher & Nikoletta Malbaski & Niki Popper & Jagpreet Chhatwal & Dan Greenberg & Josephine Mauskopf & Uwe Siebert - 513-521 The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration
by Risha Gidwani-Marszowski & Douglas K. Owens & Jeanie Lo & Jeremy D. Goldhaber-Fiebert & Steven M. Asch & Paul G. Barnett - 523-532 Physical Activity and Healthcare Costs: Projections for Poland in the Context of an Ageing Population
by Małgorzata Kalbarczyk & Joanna Mackiewicz-Łyziak - 533-543 Applying an Implementation Framework to the Use of Evidence from Economic Evaluations in Making Healthcare Decisions
by Gregory Merlo & Katie Page & Pauline Zardo & Nicholas Graves - 545-554 Willingness to Pay for Cataract Surgeries Among Patients Visiting Eye Care Facilities in Dhaka, Bangladesh
by Muhammed Nazmul Islam & Thomas Engels & Shafayet Hossain & Malabika Sarker & Atonu Rabbani - 555-567 Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia
by Carsten Hirt & Sergio Iannazzo & Silvia Chiroli & Lisa J. McGarry & Philipp Coutre & Leif Stenke & Torsten Dahlén & Jeffrey H. Lipton - 569-570 Comment on: “Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations”
by Salman Hussain & Ambrish Singh & Anwar Habib & Md Sarfaraj Hussain & Abul Kalam Najmi - 571-572 Authors’ Reply to Hussain et al.: “Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations”
by Martin Howell & Rachael Walker & Kirsten Howard
June 2019, Volume 17, Issue 3
- 265-271 Vaccination: Is There a Place for Penalties for Non-compliance?
by Tracey Chantler & Emilie Karafillakis & James Wilson - 273-284 The Value of Further Research: The Added Value of Individual-Participant Level Data
by Pedro Saramago & Manuel A. Espinoza & Alex J. Sutton & Andrea Manca & Karl Claxton - 285-294 Thopaz+ Portable Digital System for Managing Chest Drains: A NICE Medical Technology Guidance
by James Michael Evans & Alistair Ray & Megan Dale & Helen Morgan & Paul Dimmock & Grace Carolan-Rees - 295-313 An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values
by Clara Mukuria & Donna Rowen & Sue Harnan & Andrew Rawdin & Ruth Wong & Roberta Ara & John Brazier - 315-330 Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations
by Martin Howell & Rachael C. Walker & Kirsten Howard - 331-357 Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique
by Rajan Sharma & Yuanyuan Gu & Teresa Y. C. Ching & Vivienne Marnane & Bonny Parkinson - 359-370 The Association Between Adiposity and Inpatient Hospital Costs in the UK Biobank Cohort
by Padraig Dixon & George Davey Smith & William Hollingworth - 371-380 Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models
by Lan Gao & Shu-Chuen Li - 381-389 A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case–Control Study
by Mehdi Touat & Marion Opatowski & Christian Brun-Buisson & Kristel Cosker & Didier Guillemot & Jerome Salomon & Philippe Tuppin & Gregoire de Lagasnerie & Laurence Watier - 391-397 Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes
by Anthony J. Hatswell & Joshua K. Porter - 399-410 A Transparent Universal Health Coverage Index with Decomposition by Socioeconomic Groups: Application in Asian and African Settings
by Jahangir A. M. Khan & Sayem Ahmed & Tao Chen & Ewan M. Tomeny & Louis W. Niessen - 411-417 Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use
by Anna Kemp-Casey & Nicole Pratt & Emmae Ramsay & Elizabeth E. Roughead - 419-419 Correction to: Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique
by Rajan Sharma & Yuanyuan Gu & Teresa Y. C. Ching & Vivienne Marnane & Bonny Parkinson
April 2019, Volume 17, Issue 2
- 127-130 Re-design of Aged Care Environments is Key to Improved Care Quality and Cost Effective Reform of Aged and Health System Care
by Simon Eckermann & Lyn Phillipson & Richard Fleming - 131-141 ReCell® Spray-On Skin System for Treating Skin Loss, Scarring and Depigmentation after Burn Injury: A NICE Medical Technology Guidance
by Susan Caroline Peirce & Grace Carolan-Rees - 143-162 Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review
by Dominik J. Wettstein & Stefan Boes